Showing results (281-290 of 793) with videos related to
Sort By:
Pageof 80
Cancer Informatics|October 8, 2014
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myelomaRendong Yang, Li Chen, Scott Newman, et al.Clinical Lymphoma, Myeloma & Leukemia|October 9, 2012
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myelomaSundar Jagannath, Ravi Vij, A Keith Stewart, et al.Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA VaccinationDoan C Nguyen, Ian T Hentenaar, Andrea Morrison-Porter, et al.Leukemia & Lymphoma|March 15, 2022
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparisonKatja Weisel, Ajay K Nooka, Evangelos Terpos, et al.The New England Journal of Medicine|January 18, 2018
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined SignificanceRobert A Kyle, Dirk R Larson, Terry M Therneau, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|February 8, 2003
An oncolytic measles virus engineered to enter cells through the CD20 antigenAmanda D Bucheit, Shaji Kumar, Deanna M Grote, et al.Blood|July 19, 2011
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myelomaRishi K Wadhera, Robert A Kyle, Dirk R Larson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
Diagnosis and Management of Multiple Myeloma With Central Nervous System InvolvementChristopher R D'Angelo, Benjamin A Derman, Srinivas Devarakonda, et al.Blood Cancer Journal|February 10, 2021
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)Li Pang, S Vincent Rajkumar, Prashant Kapoor, et al.British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.Pageof 80